Inhalation therapy in children, with particular emphasis on nebulization, in the time of COVID-19 pandemic Review article

Main Article Content

Michał Pirożyński

Abstract

In 2019, cases of atypical interstitial pneumonia appeared in China. The clinical course of this pneumonia was quite turbulent, clinically reminiscent of another disease of SARS viral etiology. In Europe, the first COVID-19 cases have been linked to infection from people who came from China with an asymptomatic course of the disease. We are currently observing infections not only from patients from regions with high morbidity, but also from people who have never been to these regions, and who have only experienced contact with asymptomatic or scanty symptomatic people. From the beginning of the pandemic, in children we observe a different course (milder). According to the first observations from China, severe course assessed by the depth of hypoxia was observed only in 5.6% of children, and only 0.6% developed multiorgan failure or ARDS. Is inhalation therapy safe during a pandemic? Numerous doubts arose in connection with the recommendations of government agencies and international organizations regarding inhalation steroid therapy. Warnings against the use of immunosuppressive drugs in patients infected with SARS-CoV-2 virus have been transferred to all forms of steroid therapy, including inhaled steroid therapy. Inhalation therapy is safe in patients with asthma/COPD with concomitant SARS-CoV-2 infection. GINA warns on its website not to use nebulization in patients requiring inhalation treatment. This applies to one indication for nebulization – aerosolization of a short-acting β2 mimetic to stop a fit of breathlessness. During nebulization, parts of the inhaler may be contaminated. The most common source of contamination was the infected mask as well as the nebulization chamber itself. With this in mind, the possibility of contamination of the environment should be significantly reduced during the prevailing pandemic. Necessary nebulization should be carried out only with approved medicines, and the device itself should have an anti-viral filter fitted, limiting contamination of the patient’s environment. Inhalation therapy during the COVID-19 pandemic increases the requirements for the safe conduct of inhalation therapy. By following all the principles of inhalation therapy, we can safely treat our patients.

Downloads

Download data is not yet available.

Article Details

How to Cite
Pirożyński , M. (2020). Inhalation therapy in children, with particular emphasis on nebulization, in the time of COVID-19 pandemic. Alergoprofil, 16(2), 3-7. https://doi.org/10.24292/01.AP.162200520
Section
THERAPY

References

1. Hsu LY, Chia PY, Lim JF. The Novel Coronavirus (SARS-CoV-2) Epidemic. Ann Acad Med Singapore. 2020; 49: 1-3.
2. Jiang F, Deng L, Zhang L et al. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020. https://doi.org/10.1007/s11606-020-05762-w.
3. Rothe C, Schunk M, Sothmann P et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med. 2020; 382: 970-1.
4. Sinha IP, Harwood R, Semple MG et al. COVID-19 infection in children. Lancet Respir Med. 2020.
5. Lee PI, Hu YL, Chen PY et al. Are children less susceptible to COVID-19? J Microbiol Immunol Infect. 2020. http://doi.org/10.1016/j.jmii.2020.02.011.
6. Pirożyński M. Terapia wziewna – ze szczególnym uwzględnieniem steroidów – w okresie pandemii COVID-19. Alergia. 2020; 1: 4-6.
7. Lai CC, Liu YH, Wang CY et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020.
8. Recommendations for inhaled asthma controller medications – Global Initiative for Asthma – GINA. In. GINA 2020. Dolovich MB, MacIntyre NR, Anderson PJ et al. Consensus Statement: Aerosols and Delivery Devices. J Aerosol Med. 2000; 13: 291-300.
10. Grissinger M. Shared metered dose inhalers among multiple patients: can cross-contamination be avoided? P T 2013; 38: 434-42.
11. Final-COVID-19-answers-to-frequent-questions-25.3.2020. In: GINA 2020.
12. Papineni RS, Rosenthal FS. The size distribution of droplets in the exhaled breath of healthy human subjects. J Aerosol Med. 1997; 10: 105-16.
13. McGrath JA, O’Sullivan A, Bennett G et al. Investigation of the Quantity of Exhaled Aerosols Released into the Environment during Nebulisation. Pharmaceutics. 2019; 11.
14. Oie S, Makieda D, Ishida S et al. Microbial contamination of nebulization solution and its measures. Biol Pharm Bull. 2006; 29: 503-7.
15. Jarvis S, Ind PW, Thomas C et al. Microbial contamination of domiciliary nebulisers and clinical implications in chronic obstructive pulmonary disease. BMJ Open Respir Res. 2014; 1: e000018.
16. Tabatabaii SA, Khanbabaee G, Sadr S et al. Microbial contamination of home nebulizers in children with cystic fibrosis and clinical implication on the number of pulmonary exacerbations. BMC Pulm Med. 2020; 20: 33.
17. O’Toole C, Bennett G, McGrath JA et al. Analysing Fugitive Emissions from a Breath Actuated Nebuliser. J Aerosol Med Pulm Drug Deliv. 32: A30.
18. Peckham D, Williams K, Wynne S et al. Fungal contamination of nebuliser devices used by people with cystic fibrosis. J Cyst Fibros. 2016; 15: 74-7.
19. van Heerden I, van Aswegen H, van Vuuren S et al. Contamination of nebulisers and surrounding air at the bedside of mechanically ventilated patients. S Afr J Crit Care. 2017; 33: 23-7.
20. Glauser W. Communication, transparency key as Canada faces new coronavirus threat. CMAJ. 2020; 192: E171-E172.
21. Amirav I, Newhouse MT. Transmission of coronavirus by nebulizer: a serious, underappreciated risk. CMAJ. 2020; 192: E346.
22. Han ZY, Weng WG, Huang QY. Characterizations of particle size distribution of the droplets exhaled by sneeze. J R Soc Interface. 2013; 10: 20130560.
23. Pirożyński M. ABC Nebulizacji. Via Medica, Gdańsk 2015.
24. http://www.pari.com.
25. GINA. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. www.ginasthma.org. In: Global Initiative for Asthma 2019.
26. Coronavirus (COVID-19): What People With Asthma Need to Know. In: Asthma and Allergy Foundation of America 2020.